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ABSTRACT
Objective: To propose a new modality of retroperitoneal lymphadenectomy as a comple-
mentary treatment for patients with high risk, stage I nonseminomatous testicular tumor.
Materials and Methods: We studied 76 patients with stage I nonseminomatous testis
tumor (T1-T4, NX, M0) treated by orchiectomy and retroperitoneal lymphadenectomy. Among
them, 33 patients underwent unilateral retroperitoneal lymphadenectomy (URL) and 43 selective
retroperitoneal lymphadenectomy (SRL). URL consisted in removing the lymph nodes located
around the great vessel homolateral to the tumor (aorta or vena cava and iliac vessels), and ante-
rior and posterior to the contralateral great vessel (aorta or vena cava). SRL was performed re-
moving the lymph nodes located anterior and between the great vessels (aorta or vena cava) and
laterally to the homolateral great vessel, extending the distal dissection until the level of inferior
mesenteric artery. In these groups of patients, the incidence of disease recurrence, disease-free
survival index, and frequency of post-operative aspermia were assessed. Mean post-operative
follow-up time was 96 months.
Results: In the SRL group there was only 5% of aspermia versus 79% in the URL group
(p < 0.0001). Tumor recurrence was observed in only 5 of the 76 patients and was not related to
the surgical technique. The disease-free survival rate after the mean follow-up of 96 months was
similar in both groups, being 94% in the SRL group and 93% in the URL group.
Conclusion: The selective retroperitoneal lymphadenectomy constitutes an effective
technique with a lower morbidity than unilateral lymphadenectomy, representing an excellent option
for the management of patients with high-risk, stage I nonseminomatous testis tumor.
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INTRODUCTION
Nonseminomatous testis tumors represent
40 to 50% of testicular neoplasms and differ from
seminomas because they are more aggressive and
poorly radiosensitive. Their treatment is basically
surgery and/or chemotherapy, resulting in high cure
indexes (1).
For patients with stage I disease, tumor con-
fined to the scrotum, the classical treatment until 1980
was done by orchiectomy associated with bilateral
retroperitoneal lymphadenectomy (2), a procedure
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Table 1 – Distribution of the 76 patients, who underwent
unilateral retroperitoneal lymphadenectomy (URL) and
selective retroperitoneal lymphadenectomy (SRL), accord-
ing to tumor histology.
Histology                    URL             SRL    Total
Embryonic Ca
Choriocarcinoma
Teratocarcinoma
Teratoma
Mixed
 Total
with high morbidity, since it caused ejaculatory dys-
function in 75% of patients (3-5). Since the 80’s, sev-
eral authors improved the surgical technique, always
intending to decrease the morbidity caused by the
surgery. Surgeons began to perform the unilateral ret-
roperitoneal lymphadenectomy modified by Fossa et
al. (5) and the more detailed, “nerve sparing” dissec-
tion proposed by Jewet et al. (6), in order to preserve
the sympathetic nerve branches. These surgical mo-
dalities present the same oncologic results of radical
surgery, although with a variable preservation of
ejaculatory function between 62 and 88% (7-11).
Considering these results, some groups pro-
posed post-orchiectomy surveillance only for stage I
cases, with the purpose of avoiding the surgical ag-
gression and also, avoid the issue of aspermia (12,13).
However, due to the presence of occult metastases in
the retroperitoneum, which cause false-negative re-
sults in the clinical staging, recurrence occurs in about
22-35% of patients maintained under surveillance
(8,14), who will require a subsequent salvage treat-
ment. Even though patients with recurrence in
retroperitoneum present full responses above 80%
with chemotherapy, the validity of surveillance has
been questioned due to some disadvantages. Those
include, in addition to the need of subsequent che-
motherapy in cases of recurrence, the anxiety gener-
ated in the patient and the high costs of tests required
for follow-up. Thus, aiming to preserve the excellent
results of a more extensive lymphadenectomy, to mini-
mize its consequences and the drawbacks of exclu-
sive surveillance, we began to perform the so-called
selective retroperitoneal lymphadenectomy, whose
results are presented here.
MATERIALS AND METHODS
In this study we retrospectively assess 76
patients with nonseminomatous germinal testis tumor,
operated in the period from 1978 to 1994. Surgeries
were performed both by transperitoneal laparotomy
and by thoracophrenolaparotomy. Thirty-three of the
76 (43%) patients with stage I disease, (T1-T4, NX,
M0) underwent classic unilateral retroperitoneal lym-
phadenectomy (URL), between 1978 and 1986, and
43 of the 76 (57%) were treated through the selective
technique (SRL), in the period from 1986 to 1994, by
the same surgeon. Patients’ age ranged from 16 to 44
years and the median was 25 years. Among the 76
patients, 11 had embryonic carcinoma, 7 teratomas,
19 teratocarcinoma, 1 choriocarcinoma and 38 mixed
tumors (Table-1).
URL was performed as described by
Pizzocaro (4) and Fossa et al. (5). It consisted in re-
moving the lymph nodes located around the great
vessel homolateral to the tumor (aorta, vena cava and
iliac vessels), anterior and posterior to the contralat-
eral great vessel (aorta or vena cava), with the renal
hilum being the upper limit. SRL without “nerve-spar-
ing” dissection was defined as removal of the retro-
peritoneal lymph nodal chain that presents the renal
hilum as its upper limit, the inferior mesenteric ar-
tery as the lower limit, and the lateral ones according
to the side of the tumor. Right para-caval, pre-caval
and superficial inter aorta-cava and pre-aortic lymph
nodes were excised on the right side; para- and pre-
aortic, superficial inter aorta-cava and pre-caval
lymph nodes were removed on the left side, accord-
ing to the Figure-1. Thus, the nerve fillets of the
paravertebral sympathetic chain and hypogastric
plexus, contralateral to the tumor side, were always
preserved.
The occurrence of ejaculatory dysfunction
was explored between the second and the third month
post-operatively or after the conclusion of chemo-
therapy, in cases where this approach was used. Af-
ter the surgical procedures, all patients were kept on
surveillance for 2 years, consisting in dosage of α-
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Table 2 – Distribution of the 76 patients who underwent unilateral retroperitoneal lymphadenectomy and selective retro-
peritoneal lymphadenectomy, according to pathologic staging, recurrence, and number of patients who were alive at the
end of follow-up.
Stage                      N (%)   Recurrence (%)                     Alive  (%)
                          Unilateral Lymphadenectomy
pT0                 26 (79)            4                         24
pT1                   7 (21)            0                           7
                33 (100)            4 (12)                         31 (93)
                                        Selective
                           Unilateral Lymphadenectomy
pT0                30 (70)            4                         28
pT1                13 (30)            1                         13
fetoprotein and β-HCG markers every 3 months, and
computerized axial tomography of chest and abdo-
men every 6 months. After this period, markers and
image assessments were performed yearly. Adjuvant
chemotherapy was performed whenever there was a
compromised lymph node.
Figure 1 – Representation of unilateral retroperitoneal lymphadenectomy above (URL), and selective below (SRL), for tumors in the
right (R) and left (L) side
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Table 3 – Distribution of the 76 patients according to sur-
gical technique of unilateral retroperitoneal lymphadenec-
tomy (URL) or selective retroperitoneal lymphadenectomy
(SRL) compared for the presence of aspermia (p < 0.0001).
Techniques Patients  Aspermia(%)
URL      33        26 (79)
SRL      43          2 (5)
Total      76        28
RESULTS
Seventy-six patients were retrospectively
assessed as for the results of tumor recurrence, num-
ber of patients who were alive and disease-free, and
the respective rates of ejaculatory dysfunction, fol-
lowing the 2 modalities of lymphadenectomy (Tables-
2 and 3). Both groups presented similar characteris-
tics in relation to age and tumor histology. They dif-
fered only in the median of post-operative follow-up
time: in the group who underwent unilateral lym-
phadenectomy (URL) it was between 66 and 168
months, and in the SRL group it was between 62 and
146 months. Of the 33 patients who underwent URL,
4 (12%) presented systemic recurrence and were sal-
vaged with chemotherapy. The follow-up in this group
showed that 31 of the 33 (93%) patients were alive
and without evidence of disease, after the average time
of 96 months. Among the 43 patients who underwent
SRL, 13 (30%) presented microscopic disease in
retroperitoneum. Of these 13 patients, 12 underwent
adjuvant chemotherapy. One patient did not accept it
and was only observed as the others. The follow-up
in this group (SRL) identified 5 (11%) recurrences,
with one occurring in abdomen, 3 systemic and one
both abdominal and systemic, but none of them oc-
curred below the mesenteric artery, and in 4, pathol-
ogy did not detect disease in the removed lymph
nodes. All patients who presented recurrence also
received salvage chemotherapy and after the average
time of 96 months, 41 patients out of 43 (95%) were
alive and with no evidences of neoplasia.
In relation to the aspermia rate, it was noted
that in the group submitted to SRL it was only 5%,
versus 79% observed in the URL group (Table-3).
No major surgical complication was observed among
the groups.
DISCUSSION
In order to perform the lymphadenectomy
as an adjuvant treatment for orchiectomy in
nonseminomatous testis tumor, one must consider 2
fundamental biologic phenomena in relation to lymph
nodal involvement: first, that lymphatic drainage is
initially directed to lymph nodes of the renal hilum
and from there, metastases dissemination occurs, cra-
nially to the mediastinum and caudally towards the
pelvis; second, that metastases initially involve lymph
nodes located anterior to the great vessel homolat-
eral to the testicular tumor, that is, from the right side
to the region lateral to cava, anterior and between aorta
and cava, and from the left side, anterior and lateral
to aorta. Additionally, about 5% of tumors in the right
testis and 10% of tumors in the left testis (13), de-
velop metastasis in the contralateral renal hilum. For
this reason, the lymphadenectomy adjuvant to or-
chiectomy in the treatment of testicular tumor should
prioritize the removal of peri-hilar lymph nodes, in-
cluding those in the contralateral renal hilum.
Due to this behavior of the neoplasia, early
removal of potentially compromised lymph nodes can
provide, in addition to the accurate staging of the dis-
ease, the possibility of cure for the patient even after
the beginning of lymph nodal metastatic dissemina-
tion to the retroperitoneum. Following the descrip-
tion and mapping of metastatic regions described by
Ray et al. in 1974 (15) and subsequently by Donohue
et al. (16), surgeons started to increasingly perform
less extensive procedures, aiming to  decrease surgi-
cal morbidity. Such results were achieved in the fol-
low-up of our 76 patients, of whom 93% in the URL
group and 95% in the SRL group were alive and with
no evidence of disease, after the mean period of 96
months. We also confirmed the observations by other
authors (17) that the lymphadenectomy, when per-
formed through transperitoneal laparotomy, has the
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advantage of allowing bilateral dissection of lymph
nodes, however, the approach to suprahilar ones is
more difficult, when compared with
thoracophrenolaparotomy. An easier approach to
suprahilar lymph nodes is achieved by this route, with
lower morbidity. Nevertheless, more important than
the access route were the results relative to morbidity
secondary to the strategy used for performing the sur-
gery, which we will describe next.
At first, lymph nodal removal usually re-
sulted in aspermia, due to lesion of the paravertebral
ganglia, an extremely undesirable event, considering
that these patients are young individuals and in re-
productive age. And though the works by Fossa et al.
(5) indicated that, when the modified unilateral lym-
phadenectomy was used, restricting bilateral dissec-
tion, a decrease in aspermia was achieved, this com-
plication occurred in 60% of patients and was caused
by lesion of the hypogastric plexus at the level of the
aorta bifurcation . For these reason, we decided to
use the lymphadenectomy in an even more selective
way (“selective lymphadenectomy”) than the already
described one, discontinuing the dissection, in its
lower limit, at the level of the inferior mesenteric ar-
tery, in order to preserve the sympathetic ganglia and
to keep the patient’s ejaculatory capacity. In fact,
through the selective dissection of the lymphatic
chain, we reduced our aspermia index from 79% to
5%, evidencing the importance of maintaining the
hypogastric plexus. An equally important result was
that the reduction in aspermia was not accompanied
by a higher index of tumor recurrence, proving its
effectiveness as a curative treatment adjuvant to or-
chiectomy. In this study, the occult micrometastasis
rate was nearly 30% in both groups, similarly to that
observed in the literature (7,10). One must empha-
size that when lymph nodes were positive, adjuvant
chemotherapy was performed, in order to induce full
remission of disease, since from the oncologic point
of view the lymph nodal removal could have been
only partial.
A controversy we experienced as well and
must be mentioned, is the fact that by performing
surgery in all patients with stage I nonseminomatous
tumor, maybe we were “over treating” 70% of the
patients, which could be cured just with the orchiec-
tomy. But, on the other hand, we were avoiding late
recurrence, the patient’s anxiety during the follow-
up, and the high costs of subsidiary tests that are im-
posed to these patients, when an option for surveil-
lance is made. In clinical practice an effective way of
reducing the rate of unnecessary or ineffective sur-
geries, without failing to attend patients who would
need surgery, is to include “non-reliable patients”
among those with high risk for occult retroperitoneal
disease (1). According to this criterion, patients who
present factors of worse prognosis are selected for
surgery, and those are: presence of vascular invasion,
invasion of the cord and/or epididymis, extremely
high tumor markers, presence of more than 50% of
embryonic carcinoma or presence of yolk sac type
tumor (8,12,13,18) and also, patients whose clinical
follow-up could be incomplete, or not performed in
an assiduous and reliable way.
When comparing the aspermia rates ob-
tained in our group of patients with those mentioned
by other authors (7-9), we observed distinct results
according to the different surgical techniques.
Donohue et al. (8) reported keeping the ejaculation
in only 9% of cases when the dissection was bilateral
and extended to the suprahilar region, and in 18%
when it was bilateral and infrahilar, and in 75% when
the lymphadenectomy was exclusively unilateral, al-
though with no preservation of the sympathetic plexus
at the level of the bifurcation of the aorta. However,
the “nerve-sparing” procedure with preservation of
the critical segment of the hypogastric plexus was
followed by preservation of ejaculation in almost
every patient (9). In our cases, merely discontinuing
the dissection above the emergence of the inferior
mesenteric artery, with no need for a detailed identi-
fication of the nervous fibers to be spared, was enough
to, in addition to decreasing the surgical time, pro-
vide the maintenance of sperm emission in 95% of
our patients. In other words, we obtained an increase
of 20% in the rate of patients who preserved ejacula-
tion, with no impairment in disease-free survival rates,
just by limiting the surgery’s extension.
Thus we conclude that, according to our
results, selective retroperitoneal lymphadenectomy in
patients with stage I nonseminomatous testis tumor,
represents a feasible option, that is simpler than the
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procedures performed up to now, requires a shorter
surgical time and fundamentally, is followed by mini-
mal ejaculatory dysfunction. In relation to oncologic
results, the “selective lymphadenectomy” that we
began to use, provided an accurate identification of
patients who required adjuvant chemotherapy and
presented results that are equivalent to those of uni-
lateral lymphadenectomy, concerning the survival
during the period of 96 months.
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